The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated×4•Originally published 18 April 2026•Updated 20 April 2026•

1 min read

Antengene and Molecular Partners Showcase Novel Oncology Programs at AACR 2026

Key Facts

1Antengene presented three novel programs including next-generation ADCs and the AnTenGager® TCE platform at the AACR 2026 conference.

2The programs focus on Antibody-Drug Conjugates (ADC) and T-cell engagers (TCEs).

Antengene Corporation, Molecular Partners AG, and Whitehawk Therapeutics showcased preclinical data for novel oncology programs at the AACR Annual Meeting 2026 in San Diego. CStone Pharmaceuticals joined the presenters, highlighting preclinical data for three pipeline assets—CS5007, CS5006, and CS5008—utilizing its proprietary ADC platform with the CSL20 hydrophilic linker for enhanced stability. Ascentage Pharma also presented four preclinical studies, while Antengene featured its next-generation Antibody-Drug Conjugates (ADCs). Whitehawk Therapeutics demonstrated tumor regressions at low doses with its ADC portfolio, as Phase 1 trials remain ongoing. These advancements, alongside Molecular Partners' Switch-DARPin and Radio-DARPin platforms, signal robust R&D momentum across the global biotech sector.

about 1 month ago

Version History

Version 4about 1 month ago

What changed: CStone Pharmaceuticals was added to the list of biotech companies presenting preclinical data at the AACR 2026 meeting, specifically showcasing three new Antibody-Drug Conjugates (ADCs).

Version 3about 1 month ago

What changed: Ascentage Pharma was added to the list of biotechnology companies presenting at AACR 2026, specifically showcasing four new studies, along with the inclusion of the conference dates and location.

Version 2about 2 months ago

What changed: Whitehawk Therapeutics was added to the list of biotech companies presenting positive data, with details on its Carbon Bridge platform and clinical trial timelines for its lead ADC candidates.

Version 1about 2 months ago

What changed: The story was updated to include new preclinical data presentations from Molecular Partners AG at the AACR 2026 conference, specifically regarding their DARPin platform and candidates MP0632 and MP0712.